AmStem Corporation (fka AMST)

[locksflooring]

How Long has it been since the Merger http://www.otcmarkets.com/stock/AMST/company-info

With that being said, I do recall seeing in the merger between SCII and Histostem that there would be no reverse split guarantee for 2 years. Hopefully we can get some ground covered here before the deadline opens this option up.

How Many Shells
•Formerly=Stem Cell Therapy International, Inc. until 2-2010
•Formerly=Stem Cell International, Inc. until 10-05
•Formerly=Altadyne, Inc. until 10-05
•Formerly=Ultimate Direct, Inc. until 4-05
•Formerly=Ultimate Cigar Inc. until 7-99
•Formerly=Arklow Associates, Inc. until 3-97

AmStem Developmental Plans
In September 2009, Stem Cell Therapy International Inc. (OTC: AMST) executed a Reorganization and Stock Purchase Agreement with Histostem Co., Ltd. a Korean company, which will result in one of the first fully merged Pacific Rim stem cell companies and cord blood repositories with a U.S. entity. Following the execution of the Agreement, AmStem a wholly-owned subsidiary of AMST will be managing the U.S. operations of Histostem.

AmStem will develop a three-pronged, international strategic platform by using the expertise of its Management Team to improve upon the successes of Histostem:
Join the "Cosmeceuticals" Boom

* AmStem is making connections to partner with a major cosmetic distributor or department store brand, to enter the booming "cosmeceutical" market with the newest, most exciting, and most scientifically valid stem cell beauty product.
* The development of other products by Histostem's accomplished team of scientists, and/or acquisition of similar, supporting lines of products from other companies is a major objective.

High-Tech Cord Blood Banking

* AmStem will make inroads to link up Histostem's vast repository of genetically desirable Cord Blood Units (CBUs) with other international networks that provide HLA-typed cord blood samples directly to physicians for the off-label treatment of their patients. A new European Patent was recently awarded to support this.
* These high-quality CBUs, monitored and quality-controlled by a state-of-the-art cryopreservation system, will also be made available to researchers at major hospitals and universities around the world. Two recent hospitals have recently opened the gateway to the vast Chinese medical market by awarding a contract to Histostem.
* Histostem was recently granted a new US Patent for their proprietary method on deriving the maximum number of viable stem cells from a frozen cord blood specimen. This gives AmStem a strategic advantage in controlling one of the most efficient and non-controversial supply chain, storage, and delivery systems for stem cells in the world.

Exciting New Treatments

* AmStem will be generating and monitoring new, improved Clinical Trials to validate and build upon the early successes of Histostem, which has an established pipeline of promising treatments that have already been tested on real patients, including many that are patented in Korea.
* AmStem will focus on developing a novel Hair Restoration clinical trial, using a method that has already been applied for, and is imminently pending a major U.S. Patent.
* Histostem is the only company in the world to have full KFDA approval to use its cord blood derived stem cells directly for the treatment of disease. Clinical trials have been in progress for over 2 years to treat intractable conditions such as Buerger's Disease, Alzheimer's and Liver Cirrhosis, as well as Diabetes Mellitus, Hair Restoration and ALS.